{"hands_on_practices": [{"introduction": "The efficacy of checkpoint blockade therapy hinges on a fundamental principle of competitive binding. Therapeutic antibodies must effectively occupy their targets, such as the Programmed cell death protein 1 (PD-1) receptor on T cells, to prevent engagement by inhibitory ligands like Programmed death-ligand 1 (PD-L1) expressed in the tumor microenvironment. This exercise [@problem_id:2937083] provides a hands-on approach to modeling this competition, allowing you to derive the antibody concentration required to achieve a therapeutic level of target occupancy and understand how this is influenced by the local abundance of the inhibitory ligand.", "problem": "A Chimeric Antigen Receptor T cell (CAR-T) is co-administered with an antibody that blocks Programmed cell death protein 1 (PD-1) on the CAR-T surface to prevent engagement by its inhibitory ligand, Programmed death-ligand 1 (PD-L1), in the tumor microenvironment. Model the single PD-1 binding site as a receptor $R$ that can bind either the antibody $A$ or the endogenous ligand $L$ in a mutually exclusive manner. Assume well-mixed equilibrium, rapid reversible binding, and that both $[A]$ and $[L]$ are in large excess over $[R]$ so that their free concentrations equal their total concentrations. Let the dissociation constants be defined by the law of mass action as $K_{d,A} = \\frac{[R][A]}{[RA]}$ and $K_{d,L} = \\frac{[R][L]}{[RL]}$, where $[RA]$ and $[RL]$ denote the receptor bound to antibody and ligand, respectively. Define the antibody occupancy of PD-1 as $\\theta_A = \\frac{[RA]}{[R] + [RA] + [RL]}$. \n\nUsing only the definitions above and the law of mass action, derive the minimal antibody concentration $[A]_{\\min}$ required to ensure $\\theta_A \\ge t$ with $t = 0.9$, expressed in closed form as a function of $K_{d,A}$, $K_{d,L}$, and $[L]$. Explain, based on your derivation, how variation in $[L]$ shifts the required $[A]_{\\min}$ and interpret this in the context of checkpoint blockade in the tumor microenvironment. \n\nProvide your final result as a single analytical expression for $[A]_{\\min}$ that would yield units of nanomolar when $K_{d,A}$, $K_{d,L}$, and $[L]$ are each provided in nanomolar. No numerical evaluation is required, and no rounding is needed.", "solution": "The problem statement has been evaluated and is deemed valid. It is scientifically grounded in the principles of competitive receptor binding and the law of mass action, is well-posed with a unique solution, and is expressed in objective, formal language. The model is a standard and appropriate simplification used in quantitative pharmacology and cell biology. We may therefore proceed with the derivation.\n\nThe problem requires the derivation of the minimal antibody concentration, $[A]_{\\min}$, needed to achieve an antibody occupancy, $\\theta_A$, of at least $t = 0.9$ for the PD-1 receptor, $R$. The receptor can bind either an antibody, $A$, or an endogenous ligand, $L$, in a mutually exclusive manner.\n\nThe system is at equilibrium and is governed by the law of mass action. The given dissociation constants are:\n$K_{d,A} = \\frac{[R][A]}{[RA]}$\n$K_{d,L} = \\frac{[R][L]}{[RL]}$\n\nFrom these definitions, we can express the concentrations of the bound receptor complexes in terms of the free receptor concentration, $[R]$:\n$[RA] = \\frac{[R][A]}{K_{d,A}}$\n$[RL] = \\frac{[R][L]}{K_{d,L}}$\n\nThe antibody occupancy, $\\theta_A$, is defined as the fraction of total receptors bound by the antibody:\n$\\theta_A = \\frac{[RA]}{[R_{total}]}$\nwhere the total receptor concentration is $[R_{total}] = [R] + [RA] + [RL]$.\n\nSubstituting the definition of $[R_{total}]$ into the expression for $\\theta_A$:\n$\\theta_A = \\frac{[RA]}{[R] + [RA] + [RL]}$\n\nNow, we substitute the expressions for $[RA]$ and $[RL]$ derived from the dissociation constants into this equation. This allows us to express $\\theta_A$ as a function of the free ligand and antibody concentrations, $[L]$ and $[A]$, and the constants $K_{d,A}$ and $K_{d,L}$.\n$$\n\\theta_A = \\frac{\\frac{[R][A]}{K_{d,A}}}{[R] + \\frac{[R][A]}{K_{d,A}} + \\frac{[R][L]}{K_{d,L}}}\n$$\nThe concentration of free receptor, $[R]$, appears in every term in both the numerator and the denominator. It can therefore be cancelled. This is a critical step which is permissible because $[R]$ cannot be zero for any binding to occur.\n$$\n\\theta_A = \\frac{\\frac{[A]}{K_{d,A}}}{1 + \\frac{[A]}{K_{d,A}} + \\frac{[L]}{K_{d,L}}}\n$$\nThis equation describes the antibody occupancy under conditions of competitive binding. We are interested in the minimal concentration of antibody, $[A]_{\\min}$, that satisfies the condition $\\theta_A \\ge t$. This minimal concentration will be found when the equality $\\theta_A = t$ is met. We set $\\theta_A = t$ and solve for $[A]$, which we will denote as $[A]_{\\min}$.\n$$\nt = \\frac{\\frac{[A]_{\\min}}{K_{d,A}}}{1 + \\frac{[A]_{\\min}}{K_{d,A}} + \\frac{[L]}{K_{d,L}}}\n$$\nTo solve for $[A]_{\\min}$, we perform algebraic manipulation. First, multiply both sides by the denominator:\n$$\nt \\left( 1 + \\frac{[A]_{\\min}}{K_{d,A}} + \\frac{[L]}{K_{d,L}} \\right) = \\frac{[A]_{\\min}}{K_{d,A}}\n$$\nDistribute $t$ on the left-hand side:\n$$\nt + \\frac{t[A]_{\\min}}{K_{d,A}} + \\frac{t[L]}{K_{d,L}} = \\frac{[A]_{\\min}}{K_{d,A}}\n$$\nNext, we gather all terms containing $[A]_{\\min}$ on one side of the equation and all other terms on the other side.\n$$\nt + \\frac{t[L]}{K_{d,L}} = \\frac{[A]_{\\min}}{K_{d,A}} - \\frac{t[A]_{\\min}}{K_{d,A}}\n$$\nFactor out $[A]_{\\min}$ from the right-hand side:\n$$\nt \\left( 1 + \\frac{[L]}{K_{d,L}} \\right) = [A]_{\\min} \\left( \\frac{1}{K_{d,A}} - \\frac{t}{K_{d,A}} \\right)\n$$\n$$\nt \\left( 1 + \\frac{[L]}{K_{d,L}} \\right) = [A]_{\\min} \\left( \\frac{1-t}{K_{d,A}} \\right)\n$$\nFinally, we isolate $[A]_{\\min}$ to obtain the general solution:\n$$\n[A]_{\\min} = K_{d,A} \\frac{t}{1-t} \\left( 1 + \\frac{[L]}{K_{d,L}} \\right)\n$$\nThe problem specifies a target occupancy threshold of $t = 0.9$. We substitute this value into the expression.\nThe factor $\\frac{t}{1-t}$ becomes $\\frac{0.9}{1-0.9} = \\frac{0.9}{0.1} = 9$.\nThus, the specific expression for $[A]_{\\min}$ for $t=0.9$ is:\n$$\n[A]_{\\min} = 9 K_{d,A} \\left( 1 + \\frac{[L]}{K_{d,L}} \\right)\n$$\nThis is the required closed-form expression. The units are consistent, as $[L]/K_{d,L}$ is dimensionless, and $K_{d,A}$ has units of concentration.\n\nFor the interpretation, we examine the relationship between $[A]_{\\min}$ and $[L]$. The derived equation can be rewritten as:\n$$\n[A]_{\\min} = 9 K_{d,A} + 9 \\frac{K_{d,A}}{K_{d,L}} [L]\n$$\nThis is a linear equation of the form $y = c + mx$, where $y=[A]_{\\min}$ and $x=[L]$. Since the dissociation constants $K_{d,A}$ and $K_{d,L}$ are positive, the slope of this line, $9 \\frac{K_{d,A}}{K_{d,L}}$, is positive. This means that $[A]_{\\min}$ increases linearly with an increase in $[L]$.\n\nIn the context of the tumor microenvironment, $L$ represents the inhibitory ligand PD-L1, and $A$ represents the therapeutic anti-PD-1 antibody. The linear relationship demonstrates that to maintain a constant high level of PD-1 blockade on T cells ($90\\%$ occupancy), the required dose of the antibody must be increased in direct proportion to the local concentration of PD-L1. Tumors with high expression of PD-L1 present a more competitive environment for the antibody, thus necessitating a higher concentration of the therapeutic to effectively outcompete the endogenous ligand and prevent the T-cell inhibitory signal. This principle underscores why PD-L1 expression levels in the tumor are often used as a predictive biomarker for patient response to checkpoint blockade immunotherapy. A higher local concentration of PD-L1 demands a higher effective concentration of the antibody to achieve a therapeutic effect.", "answer": "$$\n\\boxed{9 K_{d,A} \\left( 1 + \\frac{[L]}{K_{d,L}} \\right)}\n$$", "id": "2937083"}, {"introduction": "A major challenge in Chimeric Antigen Receptor T-cell (CAR-T) therapy is ensuring that the engineered T cells potently attack tumor cells while sparing healthy tissues that may express the target antigen at low levels. This concept of a 'therapeutic window' is critical for patient safety. Through this biophysical modeling exercise [@problem_id:2937175], you will explore how principles like cooperative receptor signaling can be harnessed to create a sharp activation threshold, enabling CAR-T cells to distinguish between high-antigen tumors and low-antigen normal tissues.", "problem": "A Chimeric Antigen Receptor T cell (CAR-T) engages its target antigen on a cell surface and triggers intracellular signaling when sufficient receptor engagement occurs. Consider a minimal biophysical model grounded in equilibrium receptor–ligand binding and cooperative signal integration:\n\n- Assume equilibrium receptor–ligand binding characterized by a dissociation constant $K_{d}$, and let $D$ denote the effective antigen density per target cell in units consistent with $K_{d}$. Use the fractional receptor occupancy implied by equilibrium mass action as the basis for signaling.\n- Assume downstream signaling exhibits an $n$-receptor cooperative “gating” requirement, such that activation scales with the probability that $n$ independently engaging receptor–ligand interactions are simultaneously formed, with proportionality normalized to $1$.\n- Under complete Programmed cell death protein $1$ (PD-1) checkpoint blockade, assume there is no checkpoint-mediated suppression of signaling.\n\nA CAR-T product is designed to treat a tumor with antigen density $D_{T}=2.0\\times 10^{5}$ molecules per cell while sparing a critical normal tissue with antigen density $D_{N}=1.0\\times 10^{4}$ molecules per cell. The effective dissociation constant is $K_{d}=5.0\\times 10^{4}$ in the same units, the cooperativity index is $n=2$, and the activation threshold for productive T cell response is $\\theta^{\\ast}=0.30$ (dimensionless). Using only the assumptions above, determine whether it is possible for the CAR-T cell to satisfy $\\theta_T > \\theta^{\\ast}$ on tumor and $\\theta_N  \\theta^{\\ast}$ on the critical normal tissue simultaneously under full checkpoint blockade.\n\nEncode your final answer as $1$ if both inequalities can be simultaneously satisfied and $0$ otherwise. Provide a single number without units. No rounding instruction is needed because the required output is binary.", "solution": "The problem statement is subjected to validation.\n\nGivens extracted verbatim:\n- Dissociation constant: $K_{d} = 5.0 \\times 10^{4}$\n- Antigen density on tumor cell: $D_{T} = 2.0 \\times 10^{5}$\n- Antigen density on normal tissue cell: $D_{N} = 1.0 \\times 10^{4}$\n- Cooperativity index: $n = 2$\n- Activation threshold: $\\theta^{\\ast} = 0.30$\n- Condition for tumor cell activation: $\\theta_{T} > \\theta^{\\ast}$\n- Condition for normal tissue sparing: $\\theta_{N}  \\theta^{\\ast}$\n- Final answer encoding: $1$ if both conditions are met, $0$ otherwise.\n\nValidation verdict: The problem is valid. It presents a simplified but scientifically grounded biophysical model based on established principles of receptor-ligand kinetics (mass action law) and cooperative signaling. All parameters are explicitly defined, rendering the problem self-contained, well-posed, and free of ambiguity or contradiction. It is a formalizable problem within molecular and cell biology.\n\nThe solution proceeds as follows.\n\nThe core of the model rests on two principles: equilibrium binding and cooperative activation. First, we define the fractional receptor occupancy, $f$, which represents the probability that a single Chimeric Antigen Receptor (CAR) is bound to its target antigen on a cell surface. According to the law of mass action for a simple bimolecular interaction at equilibrium, the fractional occupancy is a function of the ligand concentration (here, effective antigen density $D$) and the dissociation constant $K_{d}$. The relationship is given by the standard Langmuir isotherm, also known as the Hill-Langmuir equation with a Hill coefficient of $1$:\n$$f = \\frac{D}{K_{d} + D}$$\nThis expression gives the probability of a single binding event.\n\nSecond, the problem postulates an $n$-receptor cooperative gating mechanism for T cell activation. The activation signal, denoted by $\\theta$, is stated to scale with the probability that $n$ independent receptor–ligand interactions are formed simultaneously. Given that the probability of one such interaction is $f$, the probability of $n$ independent interactions occurring concurrently is $f^{n}$. The problem specifies that the activation signal is normalized to $1$, so we can set the activation signal $\\theta$ equal to this joint probability:\n$$\\theta = f^{n} = \\left(\\frac{D}{K_{d} + D}\\right)^{n}$$\nThis equation constitutes the complete mathematical model for T cell activation under the specified assumptions.\n\nWe must now evaluate the activation signal for both the tumor tissue ($\\theta_T$) and the normal tissue ($\\theta_N$) using the provided parameters.\n\nFor the tumor tissue, the antigen density is $D_{T} = 2.0 \\times 10^{5}$. The cooperativity index is $n = 2$, and the dissociation constant is $K_{d} = 5.0 \\times 10^{4}$. Substituting these values into the activation model:\n$$\\theta_{T} = \\left(\\frac{D_{T}}{K_{d} + D_{T}}\\right)^{n} = \\left(\\frac{2.0 \\times 10^{5}}{5.0 \\times 10^{4} + 2.0 \\times 10^{5}}\\right)^{2}$$\nSimplifying the fraction within the parenthesis:\n$$\\theta_{T} = \\left(\\frac{2.0 \\times 10^{5}}{2.5 \\times 10^{5}}\\right)^{2} = \\left(\\frac{2.0}{2.5}\\right)^{2} = \\left(\\frac{4}{5}\\right)^{2} = (0.8)^{2} = 0.64$$\n\nFor the critical normal tissue, the antigen density is $D_{N} = 1.0 \\times 10^{4}$. Using the same values for $K_{d}$ and $n$:\n$$\\theta_{N} = \\left(\\frac{D_{N}}{K_{d} + D_{N}}\\right)^{n} = \\left(\\frac{1.0 \\times 10^{4}}{5.0 \\times 10^{4} + 1.0 \\times 10^{4}}\\right)^{2}$$\nSimplifying the fraction:\n$$\\theta_{N} = \\left(\\frac{1.0 \\times 10^{4}}{6.0 \\times 10^{4}}\\right)^{2} = \\left(\\frac{1}{6}\\right)^{2} = \\frac{1}{36}$$\nNumerically, this value is $\\frac{1}{36} \\approx 0.0277...$.\n\nFinally, we must check if these calculated activation levels satisfy the two required inequalities simultaneously, with the activation threshold given as $\\theta^{\\ast} = 0.30$.\n\nThe first condition is for productive activation against the tumor: $\\theta_{T} > \\theta^{\\ast}$.\nWe compare our result: $0.64 > 0.30$. This inequality is true.\n\nThe second condition is for sparing the normal tissue: $\\theta_{N}  \\theta^{\\ast}$.\nWe compare our result: $\\frac{1}{36}  0.30$. Since $\\frac{1}{36} \\approx 0.0277...$, the inequality $0.0277...  0.30$ is also true.\n\nBoth conditions, $\\theta_T > \\theta^*$ and $\\theta_N  \\theta^*$, are simultaneously satisfied. The CAR-T cell can, according to this model, discriminate between the tumor and the normal tissue. Therefore, the required output is $1$.", "answer": "$$\n\\boxed{1}\n$$", "id": "2937175"}, {"introduction": "The long-term success of Chimeric Antigen Receptor T-cell (CAR-T) therapy often depends on the persistence of the engineered cells long after infusion, providing sustained surveillance against cancer recurrence. Different intracellular signaling domains incorporated into the CAR construct, such as CD28 or 4-1BB, profoundly affect the cells' proliferation and survival rates. This practice [@problem_id:2937132] employs a straightforward yet powerful birth-death population model to quantify these dynamics, allowing you to predict and compare the in vivo persistence of different CAR-T cell designs.", "problem": "In adoptive cell therapy with Chimeric Antigen Receptor (CAR)-T cells, the intracellular costimulatory domain modulates both proliferation and apoptosis dynamics in vivo. Consider two CAR designs that differ only in their costimulatory domains: CD28 and 4-1BB. After initial tumor debulking and under conditions of low antigen, assume that the CAR-T population follows a memoryless birth–death process in which each cell independently proliferates with a per-capita rate $p$ (units $\\mathrm{day}^{-1}$) and undergoes apoptosis with a per-capita rate $a$ (units $\\mathrm{day}^{-1}$). The expected population size is denoted $N(t)$ with initial condition $N(0)=N_{0}$. A clinically relevant notion of persistence is the time required for the circulating CAR-T cell population to decline from $N_{0}$ to a functional threshold $N_{\\mathrm{th}}$.\n\nStarting only from the operational definitions of per-capita proliferation and apoptosis rates in a birth–death process and the mass-action principle for expected population change, first derive the deterministic differential equation governing $N(t)$ and its solution subject to the initial condition. Then derive an expression for the time to functional threshold $t^{\\ast}$ such that $N(t^{\\ast})=N_{\\mathrm{th}}$. Finally, using the following experimentally estimated rates measured during the post-expansion contraction phase and the same initial and threshold conditions for both constructs,\n- CD28: $p_{\\mathrm{CD28}}=0.05\\,\\mathrm{day}^{-1}$, $a_{\\mathrm{CD28}}=0.20\\,\\mathrm{day}^{-1}$,\n- 4-1BB: $p_{\\mathrm{4-1BB}}=0.03\\,\\mathrm{day}^{-1}$, $a_{\\mathrm{4-1BB}}=0.10\\,\\mathrm{day}^{-1}$,\n- initial count $N_{0}=5.0\\times 10^{7}$ cells, threshold $N_{\\mathrm{th}}=1.0\\times 10^{6}$ cells,\n\ncompute the ratio of persistence times $R=\\dfrac{t^{\\ast}_{\\mathrm{4-1BB}}}{t^{\\ast}_{\\mathrm{CD28}}}$. Round your final numerical result for $R$ to four significant figures. The ratio $R$ is dimensionless; do not include units in your final answer.", "solution": "The problem requires the derivation and solution of a deterministic model for CAR-T cell population dynamics based on a birth-death process, followed by a calculation of the relative persistence of two CAR-T cell constructs. The problem is well-posed, scientifically grounded in standard population modeling principles, and provides all necessary data for a unique solution.\n\nFirst, we derive the governing differential equation for the expected population size, $N(t)$. The process is described as a memoryless birth-death process. According to the mass-action principle, the total rate of change of the population is the difference between the total birth rate and the total death rate. The per-capita proliferation (birth) rate is given as $p$, and the per-capita apoptosis (death) rate is given as $a$. For a population of size $N(t)$, the total proliferation rate is $p \\cdot N(t)$ and the total apoptosis rate is $a \\cdot N(t)$.\n\nThe net rate of change of the population, $\\frac{dN}{dt}$, is therefore:\n$$\n\\frac{dN(t)}{dt} = p N(t) - a N(t) = (p - a) N(t)\n$$\nLet us define a net growth rate constant $k = p - a$. The equation becomes a first-order linear ordinary differential equation:\n$$\n\\frac{dN(t)}{dt} = k N(t)\n$$\nThis equation is separable. We can write it as $\\frac{dN}{N} = k \\, dt$. We integrate both sides with the initial condition $N(0) = N_0$.\n$$\n\\int_{N_0}^{N(t)} \\frac{1}{N'} dN' = \\int_{0}^{t} k \\, d\\tau\n$$\nThe integration yields:\n$$\n[\\ln|N'|]_{N_0}^{N(t)} = [k\\tau]_{0}^{t}\n$$\nSince $N(t)$ represents a cell population, it is non-negative, so we can disregard the absolute value.\n$$\n\\ln(N(t)) - \\ln(N_0) = k t\n$$\n$$\n\\ln\\left(\\frac{N(t)}{N_0}\\right) = k t\n$$\nSolving for $N(t)$ by exponentiating both sides gives the solution to the differential equation:\n$$\nN(t) = N_0 \\exp(kt) = N_0 \\exp((p-a)t)\n$$\nNext, we derive an expression for the persistence time, $t^{\\ast}$, which is defined as the time at which the population reaches the functional threshold $N_{\\mathrm{th}}$. Thus, we must solve for $t^{\\ast}$ in the equation $N(t^{\\ast}) = N_{\\mathrm{th}}$.\n$$\nN_{\\mathrm{th}} = N_0 \\exp((p-a)t^{\\ast})\n$$\nDividing by $N_0$ and taking the natural logarithm of both sides:\n$$\n\\frac{N_{\\mathrm{th}}}{N_0} = \\exp((p-a)t^{\\ast})\n$$\n$$\n\\ln\\left(\\frac{N_{\\mathrm{th}}}{N_0}\\right) = (p-a)t^{\\ast}\n$$\nThis gives the general expression for the persistence time $t^{\\ast}$:\n$$\nt^{\\ast} = \\frac{\\ln(N_{\\mathrm{th}}/N_0)}{p-a}\n$$\nThe problem states that the population declines, so $N_{\\mathrm{th}}  N_0$, which makes $\\ln(N_{\\mathrm{th}}/N_0)$ negative. For $t^{\\ast}$ to be a positive time, the net rate $(p-a)$ must also be negative, which corresponds to a decaying population.\n\nWe now use this formula to calculate the persistence times for the two CAR constructs, CD28 and 4-1BB, using the provided parameters.\nFor the CD28 construct:\n$p_{\\mathrm{CD28}} = 0.05\\,\\mathrm{day}^{-1}$ and $a_{\\mathrm{CD28}} = 0.20\\,\\mathrm{day}^{-1}$.\nThe net rate is $k_{\\mathrm{CD28}} = p_{\\mathrm{CD28}} - a_{\\mathrm{CD28}} = 0.05 - 0.20 = -0.15\\,\\mathrm{day}^{-1}$.\n\nFor the 4-1BB construct:\n$p_{\\mathrm{4-1BB}} = 0.03\\,\\mathrm{day}^{-1}$ and $a_{\\mathrm{4-1BB}} = 0.10\\,\\mathrm{day}^{-1}$.\nThe net rate is $k_{\\mathrm{4-1BB}} = p_{\\mathrm{4-1BB}} - a_{\\mathrm{4-1BB}} = 0.03 - 0.10 = -0.07\\,\\mathrm{day}^{-1}$.\n\nThe initial and threshold populations are $N_0 = 5.0 \\times 10^7$ and $N_{\\mathrm{th}} = 1.0 \\times 10^6$. The ratio is $\\frac{N_{\\mathrm{th}}}{N_0} = \\frac{1.0 \\times 10^6}{5.0 \\times 10^7} = \\frac{1}{50}$.\n\nThe persistence times are:\n$$\nt^{\\ast}_{\\mathrm{CD28}} = \\frac{\\ln(1/50)}{k_{\\mathrm{CD28}}} = \\frac{\\ln(1/50)}{-0.15} = \\frac{-\\ln(50)}{-0.15} = \\frac{\\ln(50)}{0.15}\n$$\n$$\nt^{\\ast}_{\\mathrm{4-1BB}} = \\frac{\\ln(1/50)}{k_{\\mathrm{4-1BB}}} = \\frac{\\ln(1/50)}{-0.07} = \\frac{-\\ln(50)}{-0.07} = \\frac{\\ln(50)}{0.07}\n$$\nThe problem asks for the ratio $R = \\frac{t^{\\ast}_{\\mathrm{4-1BB}}}{t^{\\ast}_{\\mathrm{CD28}}}$.\n$$\nR = \\frac{\\frac{\\ln(50)}{0.07}}{\\frac{\\ln(50)}{0.15}}\n$$\nThe term $\\ln(50)$ cancels. The ratio R is thus the ratio of the net growth rates:\n$$\nR = \\frac{t^{\\ast}_{\\mathrm{4-1BB}}}{t^{\\ast}_{\\mathrm{CD28}}} = \\frac{k_{\\mathrm{CD28}}}{k_{\\mathrm{4-1BB}}} = \\frac{-0.15}{-0.07} = \\frac{0.15}{0.07}\n$$\nNumerically:\n$$\nR = \\frac{15}{7} \\approx 2.142857...\n$$\nRounding this result to four significant figures, as required, gives $2.143$. This result indicates that the 4-1BB CAR-T cells persist more than twice as long as the CD28 CAR-T cells under these model assumptions.", "answer": "$$\n\\boxed{2.143}\n$$", "id": "2937132"}]}